Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...

Bio-Rad trades at nearly 30 times forward earnings despite recent losses, reflecting expectations for a turnaround as its ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

If you are wondering whether Bio-Rad Laboratories is starting to look attractively priced after a rough few years, this breakdown will help you put the current share price in context. The stock closed ...

During the quarter, Bio-Rad recognized a substantial change in the fair market value of its investment in Sartorius AG, contributing to a GAAP net income of $720.0 million, or $26.65 per diluted share ...

Discover the top 4 undervalued Life Sciences Tools & Services stocks for Thursday, February 19 based on AAII’s Stock Grades.